Lv4
580 积分 2024-11-21 加入
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
1个月前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
2个月前
已完结
The effects of incretins as a double-edged sword on cancer
2个月前
已完结
Tirzepatide alters oncogenic signaling pathways in colorectal cancer cells in vitro
2个月前
已关闭
941P Induction chemoimmunotherapy followed by radiotherapy and consolidation immunotherapy versus definitive concurrent chemoradiotherapy with consolidation immunotherapy for unresectable stage III non-small cell lung cancer: A single-center retrospective study
2个月前
已完结
Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study
2个月前
已完结
Camrelizumab plus chemotherapy in advanced non‐squamous non‐small cell lung cancer: Treatment response, survival pattern, and safety
2个月前
已完结
Acquired resistance in cancer: towards targeted therapeutic strategies
2个月前
已完结
Adjuvant therapy in stage IB non-small cell lung cancer: a network meta-analysis of tegafur-uracil and immune checkpoint inhibitors
3个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
